Zelira Therapeutics - Global Leader in cannabinoid-based medicine

Zelira Therapeutics Ltd is a leading global cannabinoid-based biopharmaceutical company with access to the world’s largest and fastest growing markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

Recent Video and Audio from Zelira Therapeutics

Zelira Chairman Presentation at Cantor Fitzgerald International Cannabis Forum

Zelira AGM Presentation 2022

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.

Zelira CEO Oludare Odumosu speaks with Proactive

Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.

Zelira Therapeutics Investor Presentation – Sept 2022

Hear the latest business updates from Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu.

Zelira Therapeutics Investor Presentation

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu deliver a slide presentation and answer investor questions as part of a business update.

Channel 7 News Perth

Zelira product helping young patient with autism spectrum disorder

Zelira AGM Presentation January 2022

CEO Oludare Odumosu and Chairman Osagie Imasogie presentation at the Zelira AGM 2022

Start typing and press Enter to search

Shopping Cart